Embecta (NASDAQ:EMBC) Hits New 1-Year Low – Here’s What Happened

Shares of Embecta Corp. (NASDAQ:EMBC) hit a new 52-week low on Thursday . The stock traded as low as $8.78 and last traded at $9.00, with a volume of 794567 shares traded. The stock had previously closed at $9.09.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of Embecta in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Stock Down 1.0%

The firm has a 50-day moving average price of $10.91 and a two-hundred day moving average price of $12.65. The firm has a market cap of $532.98 million, a PE ratio of 3.80 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.67 by $0.04. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm had revenue of $261.20 million during the quarter, compared to analysts’ expectations of $258.07 million. During the same period in the previous year, the business earned $0.65 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Research analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 6.7%. Embecta’s dividend payout ratio is presently 25.32%.

Hedge Funds Weigh In On Embecta

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada raised its holdings in Embecta by 38.3% in the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock valued at $232,000 after acquiring an additional 5,036 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Embecta by 3.7% in the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock valued at $2,738,000 after purchasing an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Embecta by 4.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after buying an additional 7,894 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Embecta by 224.0% during the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares during the last quarter. 93.83% of the stock is currently owned by institutional investors and hedge funds.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.